<DOC>
	<DOC>NCT00434174</DOC>
	<brief_summary>This study will evaluate the safety of everolimus in combination with pemetrexed when used as treatment in patients with non small cell lung cancer.</brief_summary>
	<brief_title>Safety of Everolimus and Pemetrexed in Lung Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Inclusion criteria: Lung cancer Only one prior regimen of chemotherapy for the treatment of non small cell lung cancer Adequate bone marrow function Adequate liver function Adequate renal function Negative serum pregnancy test Exclusion criteria: History of another primary malignancy in the last 5 years Having recently received an investigational drug Having recently received major surgery of wide field radiotherapy Chronic treatment with immunosuppressive therapy, steroids or liver enzyme modulators Severe or uncontrolled medical conditions Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Lung cancer</keyword>
	<keyword>Non small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>RAD001</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Afinitor</keyword>
	<keyword>Pemetrexed</keyword>
</DOC>